Blood Advances | 2020
Genetic factors rather than blast reduction determine outcomes of allogeneic HCT in BCR-ABL–negative MPN in blast phase.
Gupta V, Kennedy JA, Capo-Chichi J-M, Kim S, Hu Z-H, Alyea EP, Popat UR, Sobecks RM, Scott BL, Gerds AT, Salit RB, Deeg HJ, Nakamura R, Saber W
PubMed
PMID: 33170935
Abstract
Related Articles
CIBMTR Study #: CK15-03a
Dataset Files:
This dataset was collected by the Center for International Blood and Marrow Transplant Research (CIBMTR) which is supported primarily by the Public Health Service U24CA076518 from the National Cancer Institute; the National Heart, Lung, and Blood Institute; the National Institute of Allergy and Infectious Diseases; 75R60222C00011 from the Health Resources and Services Administration; N00014-23-1-2057 and N00014-24-1-2057 from the Office of Naval Research; NMDP; and the Medical College of Wisconsin. By downloading the dataset files below, you agree to the Terms and Conditions.
I agree to the Terms and Conditions; Download Dataset
I agree to the Terms and Conditions; Download Data Dictionary